U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to treat the first indication in the company’s pipeline, MPS I (Mucopolysaccharidosis type I).
In addition to the corporate headquarters in London, UK and operational offices in EU, the new office space in Philadelphia will enable IAG’ team to continue expansion of our global network of scientific and medical collaborators, while being within easy reach of strategic partners.
EB-001T and EB-001A To Be Spotlighted at The Aesthetic Meeting 2018.
Nine IAG’s abstracts, reflecting clinical research innovations of the past year, were accepted for presentation in the industry’s leading #rheumatology and #oncology scientific meetings
The works selected for publication are based on the results of innovative clinical research studies, which involve state-of-the-art and cutting-edge advanced imaging techniques, quantitative methodologies for assessment of treatment efficacy, including some that are based on machine learning and AI concepts.
Bonti Appoints Dr. Jacob Chacko to Board of Directors